Arbutus Biopharma
ABUS
55 hedge funds and large institutions have $29.7M invested in Arbutus Biopharma in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 22 reducing their positions, and 14 closing their positions.
2.9% less ownership
Funds ownership: 37.14% → 34.24% (-2.9%)
11% less funds holding
Funds holding: 62 → 55 (-7)
33% less capital invested
Capital invested by funds: $44M → $29.7M (-$14.3M)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
55% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 22
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Top Buyers
| 1 |
Bank of New York Mellon
New York
|
+$442K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$241K |
| 3 |
Jennison Associates
New York
|
+$236K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
+$141K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$68.4K |
Top Sellers
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$1.26M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$610K |
| 3 |
JP Morgan Chase
New York
|
-$360K |
| 4 |
Jane Street
New York
|
-$348K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$327K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Squarepoint
New York
| – | -$137K | -65,848 | Closed |
|
52
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$129K | -57,000 | Closed |
|
53
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$64K | -30,593 | Closed |
|
|
VF
54
Virtu Financial
New York
| – | -$51K | -24,548 | Closed |
|
55
D.E. Shaw & Co
New York
| – | -$40K | -19,300 | Closed |
|
56
Citadel Advisors
Miami,
Florida
| – | -$25K | -11,959 | Closed |
|
57
Legal & General Group
London,
United Kingdom
| – | -$11K | -5,247 | Closed |
|
|
AG
58
Aperio Group
Sausalito,
California
| – | -$3K | -1,234 | Closed |
|
|
PCP
59
Proficio Capital Partners
Newton,
Massachusetts
| – | -$1K | -495 | Closed |
|
60
Simplex Trading
Chicago,
Illinois
| – | -$434 | -252 | -38% |
|
|
NFG
61
Next Financial Group
Houston,
Texas
| – | +$345 | +200 | New |
|
ABUS Hedge Fund Activity: Q3 2019 in Review
55 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2019, worth a combined $29.7M — down 33% from $44M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ABUS and 7 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 10 added.
The largest buyer was Bank of New York Mellon, opening a new position worth an estimated $442K. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $1.26M sold.
- 55 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2019, down from 62 in Q2 2019.
- Funds reported $29.7M of Arbutus Biopharma stock for Q3 2019, down 33% quarter-over-quarter.
- 7 funds opened new Arbutus Biopharma positions in Q3 2019 and 14 closed out, a net change of -7 holders.
- The largest Arbutus Biopharma buyer in Q3 2019 was Bank of New York Mellon, an estimated $442K added.
- The largest Arbutus Biopharma seller in Q3 2019 was Foresite Capital Management IV, an estimated $1.26M sold.
Based on aggregated 13F filings for Q3 2019.